{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:30:35Z","timestamp":1791347435190,"version":"4.3.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41375-021-01449-1","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T15:17:53Z","timestamp":1634570273000},"page":"856-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5544-3410","authenticated-orcid":false,"given":"Siddharth","family":"Kunte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Keyzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4636","authenticated-orcid":false,"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ozga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"1449_CR1","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","volume":"124","author":"F Cervantes","year":"2014","unstructured":"Cervantes F. How I treat myelofibrosis. Blood. 2014;124:2635\u201342.","journal-title":"Blood"},{"key":"1449_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"1449_CR3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl J Med. 2012;366:787\u201398.","journal-title":"N. Engl J Med"},{"key":"1449_CR4","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:e317\u201324.","journal-title":"Lancet Haematol"},{"key":"1449_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015;1:643\u201351.","journal-title":"JAMA Oncol"},{"key":"1449_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl J Med. 2012;366:799\u2013807.","journal-title":"N. Engl J Med"},{"key":"1449_CR7","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.bbmt.2017.05.007","volume":"23","author":"T Jain","year":"2017","unstructured":"Jain T, Mesa RA, Palmer JM. Allogeneic stem cell transplantation in myelofibrosis. Biol Blood Marrow Transpl. 2017;23:1429\u201336.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3324\/haematol.2018.206151","volume":"104","author":"DP McLornan","year":"2019","unstructured":"McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. 2019;104:659\u201368.","journal-title":"Haematologica"},{"key":"1449_CR9","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","volume":"4","author":"K Gowin","year":"2020","unstructured":"Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4:1965\u201373.","journal-title":"Blood Adv"},{"key":"1449_CR10","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/leu.2015.233","volume":"29","author":"NM Kroger","year":"2015","unstructured":"Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group. Leukemia. 2015;29:2126\u201333.","journal-title":"Leukemia"},{"key":"1449_CR11","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3324\/haematol.2018.205211","volume":"104","author":"M Robin","year":"2019","unstructured":"Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, et al. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2019;104:1782\u20138.","journal-title":"Haematologica"},{"key":"1449_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","volume":"61","author":"RA Mesa","year":"1999","unstructured":"Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u201395. Am J Hematol. 1999;61:10\u20135.","journal-title":"Am J Hematol"},{"key":"1449_CR13","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.bbmt.2016.08.029","volume":"22","author":"A Keyzner","year":"2016","unstructured":"Keyzner A, Han S, Shapiro S, Moshier E, Schorr E, Petersen B, et al. Outcome of allogeneic hematopoietic stem cell transplantation for patients with chronic and advanced phase myelofibrosis. Biol Blood Marrow Transpl. 2016;22:2180\u20136.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR14","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/bmt.2015.172","volume":"50","author":"S Slot","year":"2015","unstructured":"Slot S, Smits K, van de Donk NW, Witte BI, Raymakers R, Janssen JJ, et al. Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis. Bone Marrow Transpl. 2015;50:1424\u201331.","journal-title":"Bone Marrow Transpl"},{"key":"1449_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transpl. 2010;16:358\u201367.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","volume":"20","author":"V Gupta","year":"2014","unstructured":"Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2014;20:89\u201397.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","volume":"124","author":"D Rondelli","year":"2014","unstructured":"Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124:1183\u201391.","journal-title":"Blood"},{"key":"1449_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11899-007-0027-x","volume":"2","author":"GA Hale","year":"2007","unstructured":"Hale GA. Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it? Curr Hematol Malig Rep. 2007;2:202\u20137.","journal-title":"Curr Hematol Malig Rep."},{"key":"1449_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1053\/beha.2001.0170","volume":"14","author":"PJ Henslee-Downey","year":"2001","unstructured":"Henslee-Downey PJ. Allogeneic transplantation across major HLA barriers. Best Pr Res Clin Haematol. 2001;14:741\u201354.","journal-title":"Best Pr Res Clin Haematol"},{"key":"1449_CR20","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","volume":"15","author":"R Szydlo","year":"1997","unstructured":"Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767\u201377.","journal-title":"J Clin Oncol"},{"key":"1449_CR21","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"J Bolanos-Meade","year":"2019","unstructured":"Bolanos-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132\u201343.","journal-title":"Lancet Haematol"},{"key":"1449_CR22","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.bbmt.2012.09.005","volume":"18","author":"RJ Jones","year":"2012","unstructured":"Jones RJ. Haploidentical transplantation: repurposing cyclophosphamide. Biol Blood Marrow Transpl. 2012;18:1771\u20132.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR23","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","volume":"33","author":"YL Kasamon","year":"2015","unstructured":"Kasamon YL, Bolanos-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33:3152\u201361.","journal-title":"J Clin Oncol"},{"key":"1449_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.bbmt.2018.10.017","volume":"25","author":"K Raj","year":"2019","unstructured":"Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, et al. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2019;25:522\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR26","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1449_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.hoc.2020.12.008","volume":"35","author":"T Jain","year":"2021","unstructured":"Jain T, Rampal RK. Accelerated and blast phase myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2021;35:325\u201335.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1449_CR28","doi-asserted-by":"crossref","unstructured":"Lowsky R, Messner H. Mechanisms and treatment of graft failure. In: (eds Forman SJ, Negrin RS, Antin JH, & Appelbaum FR) Thomas\u2019 hematopoietic cell transplantation: stem cell transplantation, I, 5th edn. Thomas\u2019 hematopoietic cell transplantation. Chichester, UK, John Wiley & Sons, Ltd., 2015. p. 944\u201358.","DOI":"10.1002\/9781118416426.ch77"},{"key":"1449_CR29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855\u201364.","journal-title":"Br J Haematol"},{"key":"1449_CR31","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333\u20138.","journal-title":"Blood"},{"key":"1449_CR32","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR33","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-04-846626","volume":"132","author":"L Masarova","year":"2018","unstructured":"Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, et al. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018;132:1664\u201374.","journal-title":"Blood"},{"key":"1449_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.bbmt.2015.09.028","volume":"22","author":"S Bregante","year":"2016","unstructured":"Bregante S, Dominietto A, Ghiso A, Raiola AM, Gualandi F, Varaldo R, et al. Improved outcome of alternative donor transplantations in patients with myelofibrosis: from unrelated to haploidentical family donors. Biol Blood Marrow Transpl. 2016;22:324\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/bmt.2009.188","volume":"45","author":"A Bacigalupo","year":"2010","unstructured":"Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transpl. 2010;45:458\u201363.","journal-title":"Bone Marrow Transpl"},{"key":"1449_CR36","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.bbmt.2020.08.024","volume":"26","author":"Y Lwin","year":"2020","unstructured":"Lwin Y, Kennedy G, Gottlieb D, Kwan J, Ritchie D, Szer J, et al. Australasian trends in allogeneic stem cell transplantation for myelofibrosis in the molecular era: a retrospective analysis from the Australasian bone marrow transplant recipient registry. Biol Blood Marrow Transpl. 2020;26:2252\u201361.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1365-2141.2008.07010.x","volume":"141","author":"SO Ciurea","year":"2008","unstructured":"Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol. 2008;141:80\u20133.","journal-title":"Br J Haematol"},{"key":"1449_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","volume":"22","author":"M Shanavas","year":"2016","unstructured":"Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors. Biol Blood Marrow Transpl. 2016;22:432\u201340.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR39","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487\u201396.","journal-title":"N Engl J Med"},{"key":"1449_CR40","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.bbmt.2007.08.006","volume":"13","author":"M Eapen","year":"2007","unstructured":"Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transpl. 2007;13:1461\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2796.2012.02547.x","volume":"272","author":"O Ringden","year":"2012","unstructured":"Ringden O, Labopin M, Beelen DW, Volin L, Ehninger G, Finke J, et al. Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. J Intern Med. 2012;272:472\u201383.","journal-title":"J Intern Med"},{"key":"1449_CR42","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","volume":"25","author":"D McLornan","year":"2019","unstructured":"McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2019;25:2167\u201371.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41409-018-0226-1","volume":"54","author":"T Jain","year":"2019","unstructured":"Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, et al. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transpl. 2019;54:204\u201311.","journal-title":"Bone Marrow Transpl"},{"key":"1449_CR44","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","volume":"22","author":"M Robin","year":"2016","unstructured":"Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, et al. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. Biol Blood Marrow Transpl. 2016;22:1206\u201311.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR45","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","volume":"12","author":"B George","year":"2010","unstructured":"George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010;12:322\u20139.","journal-title":"Transpl Infect Dis"},{"key":"1449_CR46","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bmt.2013.49","volume":"48","author":"S Ito","year":"2013","unstructured":"Ito S, Pophali P, Co W, Koklanaris EK, Superata J, Fahle GA, et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transpl. 2013;48:1313\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1449_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bbmt.2013.10.003","volume":"20","author":"S Manjappa","year":"2014","unstructured":"Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transpl. 2014;20:46\u201352.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR48","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41409-018-0172-y","volume":"53","author":"Z Peric","year":"2018","unstructured":"Peric Z, Wilson J, Durakovic N, Ostojic A, Desnica L, Vranjes VR, et al. Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 201853:1450\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1449_CR49","doi-asserted-by":"publisher","first-page":"S326","DOI":"10.1016\/j.bbmt.2018.12.527","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Cho C, Hilden P, Politikos I, Borrill T, Giralt SA, et al. Cytomegalovirus reactivation promotes CD8+ T cell subset recovery after unmodified allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:S326\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1449_CR50","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N. Engl J Med. 2017;377:2433\u201344.","journal-title":"N. Engl J Med"},{"key":"1449_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","volume":"3","author":"H Ali","year":"2019","unstructured":"Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, et al. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen. Blood Adv. 2019;3:83\u201395.","journal-title":"Blood Adv"},{"key":"1449_CR52","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","volume":"23","author":"N Kroger","year":"2017","unstructured":"Kroger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM, et al. Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2017;23:1095\u2013101.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR53","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","volume":"25","author":"R Tamari","year":"2019","unstructured":"Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, et al. Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis. Biol Blood Marrow Transpl. 2019;25:1142\u201351.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1449_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0302-9","volume":"10","author":"T Jain","year":"2020","unstructured":"Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, et al. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer J. 2020;10:36.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01449-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01449-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01449-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T10:04:29Z","timestamp":1666778669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01449-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01449-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741023617.793589629","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"21 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R.G. has received consulting fees from Abbvie, Agios, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, Daiichi Sankyo, Gilead, Incyte, Karius, Pfizer, Premier, Sierra Oncology, Stemline, and Trovagene; research support from Incyte, Genentech\/Roche, and Janssen; and owns stock in Medtronic. B.D. reports institutional research support from Takeda, Janssen, Angiocrine, Pfizer, and Poseida, and serves on the advisory board of Jazz. S.A. reports research funding through Helsinn Healthcare, Actinium Pharmaceuticals, and Pfizer and has received consulting fees from Abbvie and Agios. A.D. reports honoraria through Abbvie, Taiho, and Novartis. V.G. reports institutional research funding through Novartis and honoraria through Novartis, BMS-Celgene, Abbvie, Constellation Pharmaceuticals, and Sierra Oncology. A.T.G. reports research funding through Sierra Oncology, Pfizer, Celgene, CTI Biopharma, Incyte Corporation, Roche\/Genentech, Imago Biosciences, and Gilead Sciences, and has received consulting fees from Celgene, CTI Biopharma, AstraZeneca\/MedImmune, Incyte Corporation, and Apexx Oncology. T.J. reports institutional research support from CTI Biopharma, Incyte and Syneos Health, Consultancy with Targeted Healthcare Communications, advisory board with Care Dx, and Bristol Myers Squibb. The remaining authors do not have any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}